

Name of the Issue: Anthem Biosciences Limited	
1 Type of Issue	Initial Public offer
2 Offer Size (Rs. Mn)	33,950.00
Fresh Issue Size (Rs. Mn)	
Offer for Sale (Rs Mn)	33,950.00
*Source: Prospectus for the offer dated July 16 2025	
3 Grade of issue along with name of the rating agency	
Name	NA
Grade	NA
4 Subscription Level (Number of times)	47.50
* excluding Eligible employee and Eligible shareholder reservation and after removing multiple and duplicate bids and Source: Post Offer Report dated July 23, 2025	
5 QIB Holding (as a %age of Outstanding Capital) as disclosed to the stock exchanges	
Particulars	%
(i) On Allotment in the offer ⁽¹⁾	2.11
(ii) at the end of the 1st Quarter immediately after the listing of the issue (period ended September 30, 2025) *	8.89%
(iii) at the end of 1st FY (March 31, 2026)*	Not Available
(iv) at the end of 2nd FY (March 31, 2027)*	Not Available
(v) at the end of 3rd FY (March 31, 2028)*	Not Available
*QIB Holding not disclosed as reporting for the relevant period/fiscal year has not been completed. (1) Source: Post offer report and BSE website	

6 Financials of the issuer			
			(Rs. in Mn)
Parameters	1st FY (March 31, 2026)*	2nd FY (March 31, 2027)*	3rd FY (March 31, 2028)*
Income from operations	Not Available	Not Available	Not Available
Net Profit for the period	Not Available	Not Available	Not Available
Paid-up equity share capital	Not Available	Not Available	Not Available
Reserves excluding revaluation reserves	Not Available	Not Available	Not Available
*Financials not available as reporting for the relevant years has not been completed.			

7 Trading Status	
The equity shares of Anthem Biosciences Limited are listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") (and together with BSE the "Stock Exchanges")	
The equity shares have not been suspended or delisted.	
Particulars	Status
(i) at the end of 1st FY (March 31, 2026)*	Not Available
(ii) at the end of 2nd FY (March 31, 2027)*	Not Available
(iii) at the end of 3rd FY (March 31, 2028)*	Not Available
* Trading status not disclosed as the relevant fiscal years have not been completed.	

8 Change in Directors of Issuer from the disclosures in the offer document[#]		
Particulars	Name of Director	Appointed/Resigned
(i) at the end of 1st FY (March 31, 2026)*	NA	NA
(ii) at the end of 2nd FY (March 31, 2027)*	NA	NA
(iii) at the end of 3rd FY (March 31, 2028)*	NA	NA
* Relevant fiscal years have not been completed. # Source - Stock Exchange website		

9 Status of implementation of project/ commencement of commercial production	
(i) as disclosed in the offer document	Not applicable*
(ii) Actual implementation	Not applicable*
(iii) Reasons for delay in implementation, if any	Not applicable*
* Company did not undertake any implementation of project hence the same is not applicable	

10 Status of utilization of issue proceeds	
The objects of the Offer were to (i) to carry out the Offer for Sale of 59,575,319 Equity Shares of face value of ₹ 2 each by the Selling Shareholders aggregating to ₹ 33,950.00 million; and (ii) achieve the benefits of listing the Equity Shares on the Stock Exchanges.	

11 Comments of monitoring agency, if applicable	
(i) Comments on use of funds	NA
(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the	
(iii) Any other reservations expressed by the monitoring agency about the end use of funds	

12 Pricing Data
Designated Stock Exchange
Offer Price (Rs.)
Listing Date

BSE
570.00
21-Jul-25

Price parameters	At close of listing day (July 21, 2025)	Close of 30th calendar day from listing day ⁽²⁾ (August 20, 2025)	Close of 90th calendar day from listing day ⁽³⁾ (October 19, 2025)	As at the end of the 1st FY after the listing of the issue (31st March, 2026)		
				⁽¹⁾⁽⁴⁾		
				Closing price	High (during the FY)	Low (during the FY)
Market Price on NSE ⁽⁵⁾	840.95	818.25	772.05	Not Available	Not Available	Not Available
Nifty ⁽⁵⁾	25,453.40	25050.55	25709.85	Not Available	Not Available	Not Available
Sectoral Index ⁽⁶⁾	Not comparable to any of the available sectoral indices			Not comparable to any of the available sectoral indices		
Price parameters	As at the end of the 2nd FY after the listing of the issue (31st March, 2027) ⁽¹⁾⁽⁴⁾			As at the end of the 3rd FY after the listing of the issue (31st March, 2028) ⁽¹⁾⁽⁴⁾		
	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on NSE ⁽⁵⁾	NA	NA	NA	NA	NA	NA
Nifty ⁽⁵⁾	NA	NA	NA	NA	NA	NA
Sectoral Index ⁽⁶⁾	Not comparable to any of the available sectoral indices			Not comparable to any of the available sectoral indices		

*Source: NSE website

(1) The pricing data is not disclosed as the relevant fiscal years have not been completed

(2) 30th calendar day is taken as listing date plus 29 calendar days

(3) 90th calendar day is taken as listing date plus 89 calendar days

(4) High and Low based on intra day prices

(5) In case of reporting dates falling on a trading holiday, values for the trading day immediately preceding the trading holiday have been considered.

(6) Comparable Sectoral index is not available

13 Basis for Offer Price

Accounting ratio	As disclosed in the offer document ⁽¹⁾	At the end of 1st FY (March 31, 2026) ⁽³⁾	At the end of 2nd FY (March 31, 2027) ⁽³⁾	At the end of 3rd FY (March 31, 2028) ⁽³⁾
EPS (₹)	Issuer:			
	Consolidated (Basic)	8.07	Not Available	Not Available
	Consolidated (Diluted)	8.04	Not Available	Not Available
	Peer Group: (Diluted)			
	Syngene International Limited	12.34	Not Available	Not Available
	Sai Life Sciences Limited	8.61	Not Available	Not Available
	Cohance Lifesciences Limited (Formerly Suven Pharmaceuticals)	10.45	Not Available	Not Available
	Divi's Laboratories Limited	82.53	Not Available	Not Available
	Industry Avg:	28.48	Not Available	Not Available
Price to Earnings Ratio (P/E)	Issuer:			
	Consolidated (Consolidated)	70.9	Not Available	Not Available
	Peer Group (Consolidated)			
	Syngene International Limited	51.54	Not Available	Not Available
	Sai Life Sciences Limited	92.18	Not Available	Not Available
	Cohance Lifesciences Limited (Formerly Suven Pharmaceuticals)	97.29	Not Available	Not Available
	Divi's Laboratories Limited	83.22	Not Available	Not Available
	Industry Avg:	81.06	Not Available	Not Available
Return on Net Worth (%)	Issuer:			
	Consolidated	20.82	Not Available	Not Available
	Peer Group: (Consolidated)			
	Syngene International Limited	11.05	Not Available	Not Available
	Sai Life Sciences Limited	10.96	Not Available	Not Available
	Cohance Lifesciences Limited (Formerly Suven Pharmaceuticals)	13.61	Not Available	Not Available
	Divi's Laboratories Limited	15.35	Not Available	Not Available
	Industry Avg:	12.74	Not Available	Not Available
NAV per Equity Share (₹ per share)	Issuer:			
	Consolidated	43.1	Not Available	Not Available
	Peer Group: (Consolidated)			
	Syngene International Limited	117.42	Not Available	Not Available
	Sai Life Sciences Limited	102.12	Not Available	Not Available
	Cohance Lifesciences Limited (Formerly Suven Pharmaceuticals)	72.31	Not Available	Not Available
	Divi's Laboratories Limited	564.87	Not Available	Not Available
	Industry Avg:	214.18	Not Available	Not Available
Revenue from operation for Fiscal 2025 (in ₹million)	Issuer:			
	Consolidated	18,445.53	Not Available	Not Available
	Peer Group: (Consolidated)			
	Syngene International Limited	36,424.00	Not Available	Not Available
	Sai Life Sciences Limited	16,945.70	Not Available	Not Available
	Cohance Lifesciences Limited (Formerly Suven Pharmaceuticals)	11,975.80	Not Available	Not Available
	Divi's Laboratories Limited	93,600.00	Not Available	Not Available
	Industry Avg:	39,736	Not Available	Not Available

EV/ Operating EBITDA Ratio	Issuer:				
	Consolidated (Basic)	45.91	Not Available	Not Available	Not Available
	Peer Group (Consolidated)				
	Syngene International Limited	23.93	Not Available	Not Available	Not Available
	Sai Life Sciences Limited	39.95	Not Available	Not Available	Not Available
	Cohance Lifesciences Limited (Formerly Suven	68.44	Not Available	Not Available	Not Available
	Divi's Laboratories Limited	60.07	Not Available	Not Available	Not Available
	Industry Avg:	48.10	Not Available	Not Available	Not Available

(1) Source: Prospectus for the offer dated July 16, 2025

(2) Information sourced from financials filed by the Issuer Company and Peers on the stock exchanges

(3) Information not provided as the relevant fiscal year has not completed

Key ratios for the Company for the three fiscal years stated above shall be calculated as follows:

1. P/E ratio for the listed industry peers has been computed based on the closing market price of equity shares on National Stock Exchange of India Limited ("NSE") as on July 7, 2025 divided by the diluted earnings per share for the Fiscal ended March 31, 2025.

2. EV/ Operating EBITDA ratio for the listed industry peers has been computed as the market capitalization of the industry peers based on the closing market price of equity shares on NSE on July 7, 2025 plus the net debt as on March 31, 2025 divided by Operating EBITDA for the Fiscal ended March 31, 2025.

3. Return on Net Worth (%) = Ratio of Profit/(loss) for the year attributable to owners of the company for the Fiscal to Net Worth as of the last day of the relevant Fiscal. Net Worth means sum of equity share capital and other equity as of the last day of relevant fiscal and excludes non controlling interest.

4. Net Asset Value per Equity Share = Net worth / Weighted average number of Equity Shares outstanding during the year. Net Worth means sum of equity share capital and other equity as of the last day of relevant fiscal and excludes non controlling interest.

Any other material information

14

Date	Announcement
21 July 2025	Listing of Equity Shares of Anthem Biosciences Ltd
21 July 2025	Intimation of continuation of Ms. Divya Prasad as the Compliance Officer of Anthem Biosciences Limited pursuant to Regulation 6(1) of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements), 2015
21 July 2025	Closure of Trading Window
21 July 2025	Intimation under Regulation 8(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015
21 July 2025	Intimation of continuation of Kfin Technologies Limited as the Registrar and Share Transfer Agent of Anthem Biosciences Limited
21 July 2025	Intimation Under Regulation 30(5) Of The Securities And Exchange Board Of India (Listing Obligation And Disclosures Requirements) Regulation, 2015 - Names of the Key Managerial Personnels of the Company who are authorised to determine the materiality of an event or information and for the purpose of making disclosure to the stock exchanges under Regulation 30 of SEBI (Listing Obligations Disclosure Requirements) Regulations, 2015
08 August 2025	Board Meeting Intimation for Considering And Approval Of The Unaudited Financial Results For The Quarter Ended June 30, 2025
08 August 2025	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
13 August 2025	Board Meeting Outcome - Approval Of The Unaudited Financial Results For The Quarter Ended June 30, 2025
13 August 2025	Press release on the Unaudited Consolidated Financial Results for the quarter ended June 30, 2025.
13 August 2025	Investor Presentation on Unaudited Consolidated Financial Statement for the Quarter ended June 30, 2025
13 August 2025	Newspaper Advertisement - Unaudited Consolidated and Standalone Financial Results for the Quarter ended June 30, 2025
13 August 2025	Newspaper advertisement confirming dispatch of Postal Ballot Notice
13 August 2025	Earnings Call Transcripts for the Quarter ended June 30, 2025
08 September 2025	Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited
29 September 2025	Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
28 October 2025	Intimation of violation under Company s Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons as required under SEBI (Prohibition of Insider Trading) Regulations 2015 (SEBI PIT Regulations)
08 November 2025	the financial results for the quarter and half year ended September 30, 2025
11 November 2025	Intimation of violation under Company s Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons as required under SEBI (Prohibition of Insider Trading) Regulations 2015 (SEBI PIT Regulations)
07 January 2026	ssuance of Corporate Guarantee in favor of Citi Bank N.A and Federal Bank Limited amounting to Rs. 25 Crores and 24 Crores Respectively on behalf of Neoanthem Lifesciences Limited (Wholly Owned Subsidiary) for availing the various fund based Working Capital Credit facility availed by Wholly Owned Subsidiary
07 January 2026	Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018
27 January 2026	Anthem Biosciences Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2026 ,inter alia, to consider and approve This is to inform you that pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the Board of Directors of Anthem Biosciences Limited ("the Company") is scheduled to be held on Thursday, February 05, 2026 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025
27 January 2026	Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that an Earnings Conference Call to discuss the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2025,
05 February 2026	Submission of Unaudited Standalone and Consolidated Financial Results with Limited Review Report of Statutory Auditors for the quarter and nine months ended December 31, 2025
05 February 2026	Submission of financial results for the quarter and nine months ended December 31, 2025
05 February 2026	Press release for the financial results for the quarter and nine months ended December 31, 2025
05 February 2026	Submission of revised Press Release for the Financial Results for the quarter and nine months ended December 31, 2025 due to inadvertent missing on the complete press release
05 February 2026	Allotment of 1,03,800 equity shares, of face value Rs. 2 each, pursuant to the exercise of ESOP Options under Anthem Employee Stock Option Plan 2024

Note: The Company meets Investors/ Analysts/ Participants from time to time. Please refer to the website of the Stock Exchanges for the intimation of the schedule of such meetings and related details, as applicable. For further updates and information, please refer to the website of the Stock Exchanges i.e. www.bseindia.com and / or www.nseindia.com

Disclaimer:

The information compiled herein is in accordance with the disclosure requirements with regard to the track record of the public issues managed by JM Financial Limited ("JM Financial") arising out of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012.

This information is gathered, inter-alia, from the Prospectus of the Issuer, as amended, and from the filings made by the Issuer with the BSE Limited ("BSE") and / or the National Stock Exchange of India Limited ("NSE" and together with the BSE, the "Stock Exchanges") from time to time, price-volume data available on the website of the Stock Exchanges, other sources as disclosed herein and information / clarifications provided by the Issuer.

Nothing in this information is intended by JM Financial to be construed as legal, regulatory, accounting, tax or other advice. While reasonable care has been taken to ensure that the information provided herein is accurate and is taken from the sources that we believe are reliable, the user of this information may independently verify the accuracy of the information before taking any decision based on the above information.

Notwithstanding the above, JM Financial does not make any express or implied representation or warranty as to the authenticity, accuracy or completeness of the information or data contained herein and shall not be liable in any manner for the same. Neither JM Financial nor any of its affiliates or their directors, officers and employees will be responsible or be liable for any loss or damage including any loss of profits incidental or consequential damage, howsoever arising, suffered or incurred by any person accessing and / or using this information. The person accessing and utilizing the information is accordingly once again advised to independently verify the information and satisfy himself about the adequacy, accuracy and completeness for his specific requirement. JM Financial does not undertake to update the information contained herein except as required by applicable law or regulation.